MedPath

Raltitrexed

Generic Name
Raltitrexed
Brand Names
Tomudex
Drug Type
Small Molecule
Chemical Formula
C21H22N4O6S
CAS Number
112887-68-0
Unique Ingredient Identifier
FCB9EGG971
Background

Raltitrexed (brand name Tomudex®) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.

Indication

For the treatment of malignant neoplasm of colon and rectum

Associated Conditions
Advanced Colorectal Cancer, Pleural Mesotheliomas
Clinical Trials
Related News

The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer

Phase 2
Conditions
Pancreatic Cancer
Chemotherapy Effect
Interventions
First Posted Date
2020-10-09
Last Posted Date
2020-10-09
Lead Sponsor
Fudan University
Target Recruit Count
120
Registration Number
NCT04581876
Locations
🇨🇳

Fudan University, Shanghai, Shanghai, China

A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer

Phase 2
Conditions
Colorectal Cancer
Interventions
First Posted Date
2020-01-27
Last Posted Date
2021-08-30
Lead Sponsor
Jiangsu Cancer Institute & Hospital
Target Recruit Count
50
Registration Number
NCT04241731
Locations
🇨🇳

Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

Phase 2
Conditions
Thrombopenia
Recurrent Colorectal Carcinoma
Interventions
Radiation: radiotherapy
First Posted Date
2019-01-30
Last Posted Date
2019-01-30
Lead Sponsor
Fudan University
Target Recruit Count
50
Registration Number
NCT03823079

RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study)

Phase 2
Conditions
Colorectal Cancer
Interventions
First Posted Date
2019-01-23
Last Posted Date
2019-09-09
Lead Sponsor
Shenzhen People's Hospital
Target Recruit Count
100
Registration Number
NCT03813641
Locations
🇨🇳

Shenzhen People's Hospital, Shenzhen, Guangdong, China

Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus

Phase 2
Conditions
Esophagus Squamous Cell Carcinoma
Interventions
First Posted Date
2018-07-13
Last Posted Date
2021-04-06
Lead Sponsor
Huai'an First People's Hospital
Target Recruit Count
32
Registration Number
NCT03585530
Locations
🇨🇳

Huai'an First Hospital, Huai'an, Jiangsu, China

Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection

Phase 2
Conditions
Gastric Cancer
Interventions
Radiation: postoperative radiotherapy
First Posted Date
2018-01-05
Last Posted Date
2018-01-05
Lead Sponsor
Zhongnan Hospital
Target Recruit Count
48
Registration Number
NCT03392103
Locations
🇨🇳

Zhongnan Hopital of Wuhan University, Wuhan, Hubei, China

A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer

Phase 2
Conditions
Colorectal Cancer
Interventions
First Posted Date
2017-11-17
Last Posted Date
2017-11-17
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
30
Registration Number
NCT03344614
Locations
🇨🇳

Chinese PLA General Hospital (301 Military Hospital), Beijing, Beijing, China

Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC.

Phase 4
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Radiation: Intensity Modulated Radiotherapy
First Posted Date
2017-06-23
Last Posted Date
2020-08-07
Lead Sponsor
The First Affiliated Hospital of Dalian Medical University
Target Recruit Count
202
Registration Number
NCT03196843
Locations
🇨🇳

Lv Xiupeng, Dalian, Liaoning, China

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Phase 2
Conditions
Advanced Colorectal Cancer
Interventions
First Posted Date
2017-04-24
Last Posted Date
2021-08-30
Lead Sponsor
Jiangsu Cancer Institute & Hospital
Target Recruit Count
100
Registration Number
NCT03126071
Locations
🇨🇳

Nantong Tumor Hospital, Nantong, Jiangsu, China

🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

🇨🇳

Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China

and more 1 locations

Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2
Completed
Conditions
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Interventions
First Posted Date
2017-03-20
Last Posted Date
2021-02-01
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
41
Registration Number
NCT03083613
Locations
🇨🇳

Chinese Academy of Medical Sciences, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy